MYELODYSPLASTIC SYNDROMES

This early-phase study tests a stem cell transplant method for people with advanced blood cancers like leukemia. Instead of using strong drugs to prevent complications, doctors give specially selected immune cells (regulatory T-cells) along with regular T-cells to help the body a…

This study tests a drug called imetelstat in adults with a bone marrow disorder (MDS) who currently need regular blood transfusions because standard treatments have stopped working. The main goal is to see if imetelstat can help them go without transfusions for at least 8 weeks. …

This early-stage trial tests two drugs together—canakinumab and darbepoetin alfa—in people with a lower-risk form of myelodysplastic syndromes (MDS) whose previous treatment stopped working. The goal is to see if the combination is safe and can help the body make more red blood c…

This study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…

This study tests whether the oral drug Inqovi can help prevent myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) from coming back after a stem cell transplant. About 22 adults who have had a reduced-intensity transplant will take Inqovi as maintenance thera…

This study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. Orca-T is a custom-made cell product from a donor that includes stem cells and special immune cells. The goal is to see if it can help the transplant work better and reduce seriou…

This study compares an oral drug (ASTX727) to an IV drug (decitabine) in 72 Chinese adults with myelodysplastic syndromes, a bone marrow disorder. The goal is to see if the oral version works as well and has similar drug levels in the body. Participants will receive both treatmen…

This study offers continued treatment with the drug ASTX727 to adults with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes who were already benefiting from it in earlier studies. The main goal is to monitor long-term safety. About 332 partici…

This study looks at whether lower doses of the chemotherapy drug CPX-351 can help older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to other treatments. The goal is to control the disease while being gentler o…

This early-phase study tests the safety of combining three drugs—navitoclax, venetoclax, and decitabine—for people with advanced myeloid blood cancers like leukemia and myelofibrosis. The goal is to find a safe dose that can control the disease. Sixteen adults aged 18 and older a…

This study tests a stem cell transplant method that removes certain immune cells from the donor's blood to lower the chance of graft-versus-host disease (GvHD), a serious complication. It involves 3 patients with blood cancers or non-cancerous blood disorders who lack a perfectly…

This early-phase trial tested a new conditioning regimen combining targeted radiation (helical tomotherapy) with two chemotherapy drugs (fludarabine and melphalan) before a donor stem cell transplant in 75 patients with leukemia or myelodysplastic syndromes. The goal was to see i…

This study tests a drug called luspatercept in 6 adults with lower-risk myelodysplastic syndromes (MDS) or related blood cancers who have anemia. The goal is to see if the drug can reduce or eliminate the need for regular blood transfusions. Participants receive luspatercept plus…

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…

This study tests a drug called luspatercept in 70 adults with a low-risk form of MDS that causes anemia. The goal is to see if the drug can reduce the need for red blood cell transfusions. Participants receive the drug and are monitored for safety and effectiveness over time.

This study tests an experimental drug called AG-946 (tebapivat) in 87 adults with lower-risk myelodysplastic syndromes (MDS) who have anemia. The goal is to see if the drug can raise hemoglobin levels or help patients go without blood transfusions for at least 8 weeks. Participan…

This study aimed to test the safety and effectiveness of using banked, frozen bone marrow from partially matched deceased donors for people with blood cancers like leukemia. Patients would have received a transplant followed by drugs to prevent graft-versus-host disease. The tria…

This study tests an experimental drug called imetelstat in 46 adults with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) whose cancer did not respond to standard therapy. The goal is to see if the drug can improve blood cell counts and control the disea…

This study tests a new drug called bexmarilimab, given together with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The goal is to first find a safe dose and then see if the combination helps shrink or control the cancer. About 181 adults are taki…

This early study tests a chemotherapy drug called CPX-351 in 20 adults aged 18-70 with high-risk myelodysplastic syndrome (MDS) who are eligible for a stem cell transplant. The main goal is to see if the drug is safe and tolerable. Researchers also look at how many patients achie…

This early-phase study tests a new treatment for people whose blood cancer (like AML or MDS) has come back after a stem cell transplant. The treatment combines a special type of donor immune cell infusion with an immunotherapy drug called ipilimumab. The main goal is to find the …

This study tests whether stem cells from donated umbilical cords are safe and can help people with myelodysplastic syndrome (MDS), a bone marrow disorder. About 40 participants with moderate to severe symptoms will receive the stem cell treatment. Researchers will monitor side ef…

This study tests a drug called eltrombopag in adults with a low-risk form of myelodysplastic syndromes (MDS) who regularly need platelet transfusions. The goal is to see if the drug can help patients go at least 8 weeks without a transfusion. The study is being done in Japan and …

This study tests whether a higher approved dose of the drug luspatercept can help people with a low-risk form of myelodysplastic syndromes (MDS) go without red blood cell transfusions for at least 8 weeks. About 106 adults who currently need regular transfusions will receive the …

This study tests whether giving a drug that changes how DNA is read (called a DNA methyltransferase inhibitor) before standard chemotherapy can help children with newly diagnosed acute myeloid leukemia. About 206 participants will receive either azacitidine or decitabine for five…

This study looks at the long-term safety of the drug sabatolimab in people with certain blood cancers (myelodysplastic syndromes or chronic myelomonocytic leukemia) who have already been helped by the drug in a previous study. About 33 participants will continue receiving sabatol…

This study tests whether an oral chemotherapy drug (azacitidine, also called ONUREG) can help people with a bone marrow disorder called myelodysplastic syndrome (MDS) that is low or intermediate risk. About 230 adults will receive either the drug or a placebo, along with standard…

This study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…

This study tests whether adding a precise, high-dose radiation treatment to the whole bone marrow before a stem cell transplant can help people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) live longer without their cancer returning. About 38 adul…

This study tests whether luspatercept works better than epoetin alfa for treating anemia in adults with a certain type of low-risk MDS who have not needed blood transfusions or prior anemia drugs. About 360 participants will receive one of the two drugs, and researchers will trac…

This study tests a way to make stem cell transplants safer for people with myelodysplastic syndrome (MDS), a type of blood cancer. The method uses a device to remove immune cells from the donor's blood before transplant, which may lower the risk of graft-versus-host disease (GVHD…

This early-phase study tests whether the drug itacitinib can prevent cytokine release syndrome (a severe inflammatory reaction) and reduce the need for other immune-suppressing medicines after a stem cell transplant in people aged 60 and older with certain blood cancers. Particip…

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers or disorders. About 43 participants will receive vo…

This early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…

This study looks at whether starting palliative care early can help adults with aggressive leukemias or myelodysplastic syndrome (MDS) have a better end-of-life experience. Researchers will compare where patients die (home, hospice, or hospital) and how often they need hospital c…

This study tests a program that combines mindfulness and music therapy, delivered through an app or website, for people undergoing a stem cell transplant. The goal is to see if it helps improve quality of life and reduce symptoms like pain. About 60 adults with certain blood canc…

This study looks at whether adding a palliative care team to standard leukemia care helps people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) feel better and have better end-of-life planning. About 320 patients receiving non-intensive therapy will take part…

This study follows 300 people with low blood cell counts (ICUS or CCUS) that do not yet meet the criteria for myelodysplastic syndromes (MDS). The goal is to track how often these conditions progress to MDS over time. Participants are observed without receiving any experimental t…

This early-stage study tests whether atorvastatin, a widely used cholesterol medication, can reduce levels of a faulty protein called p53 in people with various cancers, including solid tumors and acute myeloid leukemia. About 50 participants will take the drug for 1 to 4 weeks b…

This study aims to uncover why blood and bone marrow cancers develop by analyzing genetic and protein abnormalities in cancer cells. Researchers will collect samples from 5,000 people with these cancers to identify key mutations and test if existing drugs can reverse them. Partic…

This study looks at how blood cancers and stem cell transplants affect muscle function in 144 patients. Researchers want to see if muscle health can help predict recovery and complications after transplant. The goal is to better understand and support patients through their treat…

This study looks at whether testing drugs on a patient's blood cells in a lab can predict how well their chemotherapy will work. Researchers will collect blood samples from 80 adults with acute myeloid leukemia or myelodysplastic syndromes before treatment. The goal is to find be…

This study aims to understand the genetic and molecular changes that happen in people with bone marrow failure disorders, such as aplastic anemia and myelodysplastic syndromes. Researchers will analyze blood and bone marrow samples from up to 1,400 participants aged 2 and older, …

This study was designed to learn how the protein calprotectin changes blood stem cells in people with severe COVID-19 or certain blood cancers. Researchers planned to compare blood stem cells from patients with severe COVID-19, blood cancers, and healthy volunteers. The study was…

This study follows 120 people with different cancers (like leukemia, lymphoma, and solid tumors) who already received treatment in an earlier study. The main goal is to track serious side effects and other health issues over time. No new treatment is given—just ongoing safety mon…